Pay in 4 interest-free payments of $7.47 Learn more
Ships within 48 hours · Estimated delivery Aug 15 - Aug 20
Use an insulin cooling case or insulated pouch with a pre-chilled ice pack for the journey
In 2023, Pfizer published research papers successively, reporting the results of randomized clinical trials on the efficacy and safety of PF-06882961 for blood sugar control in patients with type 2 diabetes, the safety, tolerability, pharmacokinetics, and pharmacodynamics of PF-06882961 in Japanese adults with type 2 diabetes from a phase 1 clinical trial, and the results of a 12-week randomized, placebo-controlled, dose-escalation phase 2 trial on the tolerability, safety, and pharmacodynamics of PF-06882961 for the treatment of type 2 diabetes
Comprising the active ingredient semaglutide , its become a talked about medication due to its effectiveness and FDA-approved status for diabetes control
Clinical Pharmacokinetics, 60(1), 53-63
